Tags

Type your tag names separated by a space and hit enter

Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15; 10(5):531-9.JA

Abstract

In untreated, asymptomatic human immunodeficiency virus type 1 (HIV-1) infection, elevated serum concentrations of soluble receptors for tumor necrosis factor (sTNFR) types I and II are associated with progression to AIDS. To assess the utility of sTNFRs as markers for the assessment of antiretroviral treatment, sTNFRs were sequentially determined in 47 asymptomatic HIV-1-infected men, who participated in a double-blind, randomized, placebo-controlled study. Progression to AIDS or severe AIDS-related complex occurred in six zidovudine (ZDV)- and six placebo-treated subjects. During ZDV treatment (n = 28) both types of sTNFRs declined compared with baseline and placebo, whereas they increased during placebo treatment (n = 19). A sustained decline of sTNFRs occurred only in subjects who experienced no disease progression. During the first 3 months of ZDV treatment, the hazard ratio for disease progression when sTNFR type II rose above the baseline value plus 5% was significantly increased (hazard ratio: approximately 25; 95% confidence interval: approximately 1.5-400; p < 0.03). Simultaneously determined CD4+ counts and serum neopterin levels showed a similar pattern in progressors and nonprogressors. Thus, in contrast to CD4+ counts and neopterin levels, sTNFR concentrations, especially those of the type II STNFR, appear to be valuable surrogate markers for monitoring the efficacy of ZDV treatment in asymptomatic HIV-1 infection.

Authors+Show Affiliations

Godfried MH
Department of Internal Medicine, University of Amsterdam, The Netherlands.
van der Poll T
No affiliation info available
Mulder JW
No affiliation info available
Weverling GJ
No affiliation info available
Endert E
No affiliation info available
Lange JM
No affiliation info available
Sauerwein HP
No affiliation info available

MeSH

AIDS-Related ComplexAcquired Immunodeficiency SyndromeAdultAntiviral AgentsBiomarkersBiopterinCD4 Lymphocyte CountDisease ProgressionDouble-Blind MethodFollow-Up StudiesHIV Core Protein p24HIV InfectionsHIV-1HumansMaleNeopterinReceptors, Tumor Necrosis FactorSolubilityZidovudine

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8548332

Citation

Godfried, M H., et al. "Soluble Tumor Necrosis Factor Receptors as Surrogate Markers for the Assessment of Zidovudine Treatment in Asymptomatic HIV-1 Infection." Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association, vol. 10, no. 5, 1995, pp. 531-9.
Godfried MH, van der Poll T, Mulder JW, et al. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10(5):531-9.
Godfried, M. H., van der Poll, T., Mulder, J. W., Weverling, G. J., Endert, E., Lange, J. M., & Sauerwein, H. P. (1995). Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association, 10(5), 531-9.
Godfried MH, et al. Soluble Tumor Necrosis Factor Receptors as Surrogate Markers for the Assessment of Zidovudine Treatment in Asymptomatic HIV-1 Infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15;10(5):531-9. PubMed PMID: 8548332.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection. AU - Godfried,M H, AU - van der Poll,T, AU - Mulder,J W, AU - Weverling,G J, AU - Endert,E, AU - Lange,J M, AU - Sauerwein,H P, PY - 1995/12/15/pubmed PY - 1995/12/15/medline PY - 1995/12/15/entrez SP - 531 EP - 9 JF - Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association JO - J Acquir Immune Defic Syndr Hum Retrovirol VL - 10 IS - 5 N2 - In untreated, asymptomatic human immunodeficiency virus type 1 (HIV-1) infection, elevated serum concentrations of soluble receptors for tumor necrosis factor (sTNFR) types I and II are associated with progression to AIDS. To assess the utility of sTNFRs as markers for the assessment of antiretroviral treatment, sTNFRs were sequentially determined in 47 asymptomatic HIV-1-infected men, who participated in a double-blind, randomized, placebo-controlled study. Progression to AIDS or severe AIDS-related complex occurred in six zidovudine (ZDV)- and six placebo-treated subjects. During ZDV treatment (n = 28) both types of sTNFRs declined compared with baseline and placebo, whereas they increased during placebo treatment (n = 19). A sustained decline of sTNFRs occurred only in subjects who experienced no disease progression. During the first 3 months of ZDV treatment, the hazard ratio for disease progression when sTNFR type II rose above the baseline value plus 5% was significantly increased (hazard ratio: approximately 25; 95% confidence interval: approximately 1.5-400; p < 0.03). Simultaneously determined CD4+ counts and serum neopterin levels showed a similar pattern in progressors and nonprogressors. Thus, in contrast to CD4+ counts and neopterin levels, sTNFR concentrations, especially those of the type II STNFR, appear to be valuable surrogate markers for monitoring the efficacy of ZDV treatment in asymptomatic HIV-1 infection. SN - 1077-9450 UR - https://www.unboundmedicine.com/medline/citation/8548332/Soluble_tumor_necrosis_factor_receptors_as_surrogate_markers_for_the_assessment_of_zidovudine_treatment_in_asymptomatic_HIV_1_infection_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓3]

Related Citations

More